Intellipharmaceutics International Stock Fundamentals
| IPCIFDelisted Stock | USD 0.04 0.00 0.00% |
Intellipharmaceutics International fundamentals help investors to digest information that contributes to Intellipharmaceutics' financial success or failures. It also enables traders to predict the movement of Intellipharmaceutics OTC Stock. The fundamental analysis module provides a way to measure Intellipharmaceutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intellipharmaceutics otc stock.
Intellipharmaceutics |
Intellipharmaceutics International OTC Stock Current Valuation Analysis
Intellipharmaceutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Intellipharmaceutics Current Valuation | 4.47 M |
Most of Intellipharmaceutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intellipharmaceutics International is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Intellipharmaceutics International has a Current Valuation of 4.47 M. This is 99.97% lower than that of the Pharmaceuticals sector and 99.9% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.97% higher than that of the company.
Intellipharmaceutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Intellipharmaceutics's current stock value. Our valuation model uses many indicators to compare Intellipharmaceutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Intellipharmaceutics competition to find correlations between indicators driving Intellipharmaceutics's intrinsic value. More Info.Intellipharmaceutics International is rated fifth overall in return on asset category among its peers. It also is rated fifth overall in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Intellipharmaceutics' earnings, one of the primary drivers of an investment's value.Intellipharmaceutics Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intellipharmaceutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Intellipharmaceutics could also be used in its relative valuation, which is a method of valuing Intellipharmaceutics by comparing valuation metrics of similar companies.Intellipharmaceutics is currently under evaluation in current valuation category among its peers.
Intellipharmaceutics Fundamentals
| Return On Asset | -0.98 | ||||
| Operating Margin | (106.06) % | ||||
| Current Valuation | 4.47 M | ||||
| Shares Outstanding | 33.09 M | ||||
| Shares Owned By Insiders | 1.70 % | ||||
| Shares Owned By Institutions | 11.09 % | ||||
| Number Of Shares Shorted | 714 K | ||||
| Price To Earning | (0.50) X | ||||
| Price To Sales | 66.19 X | ||||
| Gross Profit | 1.4 M | ||||
| EBITDA | (4.45 M) | ||||
| Net Income | (5.15 M) | ||||
| Cash And Equivalents | 79.65 K | ||||
| Total Debt | 2.01 M | ||||
| Debt To Equity | 165.20 % | ||||
| Current Ratio | 0.05 X | ||||
| Book Value Per Share | (0.31) X | ||||
| Cash Flow From Operations | (2.46 M) | ||||
| Short Ratio | 0.39 X | ||||
| Earnings Per Share | (0.16) X | ||||
| Target Price | 25.0 | ||||
| Number Of Employees | 11 | ||||
| Beta | 1.0 | ||||
| Market Capitalization | 2.02 M | ||||
| Total Asset | 2.1 M | ||||
| Retained Earnings | (86.55 M) | ||||
| Working Capital | (5.62 M) | ||||
| Current Asset | 1.41 M | ||||
| Current Liabilities | 7.02 M | ||||
| Z Score | -65.8 | ||||
| Net Asset | 2.1 M |
About Intellipharmaceutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intellipharmaceutics International's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intellipharmaceutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intellipharmaceutics International based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. The company was founded in 1998 and is based in Toronto, Canada. Intellipharmaceutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 11 people.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in Intellipharmaceutics OTC Stock
If you are still planning to invest in Intellipharmaceutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intellipharmaceutics' history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |